(Q44230242)

1 December 2017

title

Rivastigmine in the treatment of Huntington's disease (English)

1 reference

1 December 2017

0 references

U Rot

1

1 reference

1 December 2017

J Kobal

2

1 reference

1 December 2017

A Sever

3

1 reference

1 December 2017

Z Pirtosek

4

1 reference

1 December 2017

A Mesec

5

1 reference

1 December 2017

publication date

1 November 2002

1 reference

European Journal of Neurology

1 December 2017

published in

1 reference

1 December 2017

volume

9

1 reference

1 December 2017

issue

6

1 reference

1 December 2017

page(s)

689-690

1 reference

Donepezil for Huntington's disease

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00447_4.X

Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00447_4.X

Studies on neurotransmitter markers and striatal neuronal cell density in Huntington's disease and dentatorubropallidoluysian atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00447_4.X

Huntington's disease: New approaches to an old problem: The Robert Wartenberg Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00447_4.X

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00447_4.X

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00447_4.X

10.1046/J.1468-1331.2002.00447_4.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference